subscribeSubscribe
Tracking a successful DLBCL assault in PhII, MorphoSys out to OK for MOR208

Tracking a successful DLBCL assault in PhII, MorphoSys out to OK for MOR208
S. Owermohle PLATFORM
14 Mar 2018
Share Share
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report

Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Angus Liu FIERCE PHARMA
06 Jan 2018
Share Share
AbbVie`s Q4 sales miss the mark as cancer, hep C meds lag

AbbVie`s Q4 sales miss the mark as cancer, hep C meds lag
Carly Helfand FIEREC PHARMA
27 Jan 2017
Share Share
Conitec Approves Incorporation by SUS of AbbVie`s Drug for Chronic Hepatitis C

Conitec Approves Incorporation by SUS of AbbVie`s Drug for Chronic Hepatitis C
PR NEWSWIRE
05 Dec 2016
Share Share
EU Health Regulator Warns Some Hep C Drugs Could Reactivate Hep B

EU Health Regulator Warns Some Hep C Drugs Could Reactivate Hep B
VL Nathan REUTERS
03 Dec 2016
Share Share
AbbVie Receives FDA Approval Of Viekria XR For The Treatment of Genotype 1 Chronic Hepatitis C

AbbVie Receives FDA Approval Of Viekria XR For The Treatment of Genotype 1 Chronic Hepatitis C
FDA
22 Jul 2016
Share Share
AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK

AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK
PR NEWSWIRE
26 Apr 2016
Share Share
Sanofi introduces new Priftin packaging to treat latent tuberculosis

Sanofi introduces new Priftin packaging to treat latent tuberculosis
PR NEWS WIRE
03 Dec 2015
Share Share
AbbVie Demonstrate Commitment to Hep C Patients with New Data on VIEKIRA PAK™

AbbVie Demonstrate Commitment to Hep C Patients with New Data on VIEKIRA PAK™
PR NEWSWIRE
01 Oct 2015
Share Share
NHS England stumps up £190m for hep C therapy

NHS England stumps up £190m for hep C therapy
Selina Mckee PHARMATIMES
12 Jun 2015
Share Share